Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04796935
Other study ID # INT-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 4, 2021
Est. completion date November 24, 2021

Study information

Verified date June 2024
Source IntuiTap Medical, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare the VerTouch device to the conventional palpation technique for performing diagnostic and therapeutic neuraxial procedures.


Description:

Neuraxial procedures, in which a needle is inserted into the spinal canal through a gap in the vertebrae, are performed at a rate of nearly 13 million per year in the US, across a myriad of diagnostic and therapeutic clinical scenarios. The standard of care involves manual palpation of the patient's back to detect the spinous processes (SPs) and estimate the location of the interspinous needle insertion site. While providers are trained to perform these procedures with meticulous precision and attention to detail, this technique remains highly inaccurate, often requiring multiple insertion attempts to properly place the needle. These attempts lead to patient pain and complications, such as traumatic taps and post-dural puncture (PDPH) headaches; unpredictable procedure times; and poor facility throughput. The VerTouch device uses tactile imaging to offer a non-invasive, untethered, non radiation-producing solution for visualizing spinal anatomy in order to identify an ideal location for needle placement in a neuraxial procedure. The device can be used to mark the identified site with a surgical marker, or to begin placement of a needle or introducer at that site. Study participants will be recruited in two parallel cohorts: the control (palpation) group or the tactile imaging (VerTouch) group, further stratified by procedure setting, including emergency medicine, neurology, and anesthesiology. Once an insertion site is marked with a marker or shallow placement of a needle or introducer, the procedure will continue in the usual manner for subjects in both groups.


Recruitment information / eligibility

Status Completed
Enrollment 95
Est. completion date November 24, 2021
Est. primary completion date November 24, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Males and females aged 18 years and above, inclusive 2. Subjects scheduled for one of the following procedures: - Diagnostic LP (collection of CSF and/or measurement of ICP to diagnose hemorrhaging or neurological infections) - Therapeutic LP (intrathecal injection of therapeutic agents; drainage of CSF to treat pseudotumor cerebri) - Planned orthopedic or obstetric procedure, such as labor/induction, cesarean section, hysterectomy, or total hip/knee replacement, with neuraxial anesthesia (injection of anesthetic into spinal and/or epidural space to reduce pain during procedure) - Epidural blood patch (use of autologous blood to close holes in the dura mater and relieve PDPH) 3. Subjects having a BMI =42kg/m2 Exclusion Criteria: 1. Patient does not provide informed consent 2. Skin or soft tissue infection near the puncture site 3. Allergy to local anesthetic 4. Uncorrected coagulopathy 5. Acute spinal cord trauma 6. History of lumbar spinal surgery 7. Prior known failed neuraxial anesthesia 8. Diagnosed scoliosis, thoracic kyphosis, lumbar lordosis, scleroderma, or ankylosing spondylitis, or lumbar spinal stenosis 9. Incarcerated subjects

Study Design


Intervention

Device:
Tactile Imaging (VerTouch)
VerTouch device used to identify and mark, or begin placement of a needle at an insertion site. After the device is taken off the back, the procedure will continue in the usual manner.
Other:
Control (palpation)
Control, palpation used to identify and mark an insertion site.

Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina
United States University of Texas Health Science Center Houston Texas
United States Rhode Island Hospital Providence Rhode Island

Sponsors (2)

Lead Sponsor Collaborator
IntuiTap Medical, Inc ICON plc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Localization Time Time from first touch of draped patient to identification of an insertion site; for VerTouch, this is the time from VerTouch device placement to movement of the applicator to the identified insertion site. End of procedure, 1 per subject
Other Insertion Time Time from retrieval of marker or local-anesthetic assembly until no further needle advancements are made. End of procedure, 1 per subject
Other Total Procedure Time From positioning of the patient to removal of the drape from the subject's back. End of procedure, 1 per subject
Other Bone Contacts Number of times the needle contacts bone, counted until confirmation of spinal canal access can be assessed. End of procedure, 1 per subject
Other Incidence of Unintended Dural Puncture A case that results in puncture of the dura when it is not intended (i.e., in an epidural procedure). End of procedure, 1 per subject
Other Incidence of Paresthesia During Needle Insertion A case in which paresthesia is experienced during needle insertion. End of procedure, 1 per subject
Other Incidence of Traumatic Tap A case that results in visible blood aspiration. End of procedure, 1 per subject
Other Incidence of Referral to Radiology A case in which the provider cannot perform the procedure at the bedside and refers the subject to radiology for the procedure to be completed under fluoroscopic guidance. End of procedure, 1 per subject
Other Incidence of Conversion From Spinal to Epidural A case that the provider opts to complete using epidural anesthesia instead of spinal anesthesia. End of procedure, 1 per subject
Other Incidence of Post-dural Puncture Headache A case that results in the patient experiencing one or more headache of any level of severity after the procedure and/or at follow-up. Follow up, 3±2 days after procedure, 1 per subject
Primary Number of Insertion Attempts Any forward movement of the needle following puncture of the skin, counted until confirmation of spinal canal access can be assessed. End of procedure, 1 per participant
Secondary Incidence of First-insertion Success A case that does not require any reinsertions, but can include any number of redirections. End of procedure, 1 per subject
Secondary Number of Redirections Any forward movement of the needle in a new direction not preceded by withdrawal from the skin, counted until confirmation of spinal canal access can be assessed. End of procedure, 1 per subject
Secondary Number of Passes Any forward movement of the needle, calculated as the sum of insertions and redirections. End of procedure, 1 per subject
Secondary Incidence of First-pass Success A case that does not require reinsertions or redirections. End of procedure, 1 per subject
Secondary Subject Discomfort During Landmarking Evaluated using a 10-point Numeric Pain Rating Scale, where 1 is equivalent to no pain and 10 is equivalent to the worst possible pain. End of procedure, 1 per subject
Secondary Provider Confidence With the Identified Insertion Site Evaluated using a 1-5 point Numeric Rating Scale where 1 is equivalent to not at all confident and 5 equivalent to completely confident. End of procedure, 1 per subject
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients